BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ActiveSight Signs Multi-Target Crystallography Service Agreement With Lexicon Pharmaceuticals, Inc. (LEXG)


1/5/2007 11:56:57 AM

SAN DIEGO, Jan. 5 /PRNewswire/ -- ActiveSight announced that it has signed an expanded crystallography services agreement with Lexicon Pharmaceuticals. The agreement, the third between the companies, covers co-crystallography services for multiple proprietary targets of Lexicon Pharmaceuticals. ActiveSight's second co-crystallography agreement with Lexicon was announced in April of 2005. Lexicon Pharmaceuticals is the medicinal chemistry division of Lexicon Genetics Incorporated.

"We are delighted that Lexicon Pharmaceuticals has decided to expand their relationship with ActiveSight. We look forward to providing continued structural biology support for Lexicon's drug discovery programs," stated Duncan McRee, President of ActiveSight.

ABOUT ACTIVESIGHT

ActiveSight(TM) offers full gene-to-structure protein crystallography services, including fragment-based screening utilizing the Rigaku FR-E SuperBright(TM) generator and the ACTOR(TM) automation system. For more information visit www.active-sight.com.

ActiveSight and ACTOR are trademarks of Rigaku.

Source: ActiveSight



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES